Skip to main content
JIANGSU SIHUAN BIOENGINEERING CO.,LTD logo

JIANGSU SIHUAN BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000518 ISIN · CNE0000001P8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,779 across all filing types
Latest filing 2022-06-01 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 000518

About JIANGSU SIHUAN BIOENGINEERING CO.,LTD

https://www.000518shsw.com

Jiangsu Sihuan Bioengineering Co., Ltd. specializes in the research, development, and production of biopharmaceutical products and traditional Chinese medicines. The company’s core product line features genetic engineering drugs, including recombinant human interleukin-2 (rhIL-2) and recombinant human granulocyte colony-stimulating factor (rhG-CSF). Its manufacturing capabilities encompass various dosage forms such as injections, capsules, and tablets, adhering to rigorous quality standards. In addition to its pharmaceutical core, the company manages ecological restoration and landscape engineering initiatives. The organization focuses on leveraging biotechnology to provide therapeutic solutions for oncology and immune-related conditions, maintaining a commitment to scientific innovation and clinical efficacy.

Recent filings

Filing Released Lang Actions
第九届董事会第十三次会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of resolutions passed at the 13th meeting of the 9th Board of Directors of Jiangsu Sihuan Bio. It includes details about the nomination of an independent director and the proposal to convene the 2021 Annual General Meeting. The document is short (657 characters) and primarily reports board decisions and meeting outcomes. It does not contain financial statements or detailed management discussion. It is not a full Annual Report or Interim Report. It is not a call transcript or earnings release. The content fits the category of Board/Management Information (MANG), as it announces changes and proposals related to the board of directors.
2022-06-01 Chinese
江苏四环生物股份有限公司2021年度营业收入扣除事项的专项审核报告
Regulatory Filings Classification · 90% confidence The document contains only references to omitted pictures and no textual content or financial data. It is very short (541 characters) and does not contain any report, announcement, or detailed information. There is no indication of the document type or any specific filing content. Given the lack of substantive content, the document does not fit any specific report category and defaults to Regulatory Filings (RNS) as a fallback category.
2022-05-27 Chinese
2021年年度报告摘要
Annual Report Classification · 100% confidence The document is titled "江苏四环生物股份有限公司 2021 年年度报告摘要" which translates to "Jiangsu Sihuan Biological Co., Ltd. 2021 Annual Report Summary." It contains detailed financial data for the year 2021, including total assets, net profit, earnings per share, quarterly financial data, and shareholder information. The document references the full annual report and includes audit opinions, business overview, industry analysis, and financial performance metrics. The length of the document (15,000 characters) and the presence of substantive financial data and analysis confirm it is not merely an announcement or summary notice but a full annual report. Therefore, the document fits the definition of an Annual Report (10-K). FY 2021
2022-05-27 Chinese
关于2021年年度报告全文及摘要的更正公告
Annual Report Classification · 95% confidence The document is titled as a correction announcement for the 2021 Annual Report and its summary by Jiangsu Sihuan Bioengineering Co., Ltd. It contains detailed corrections to financial data and accounting figures originally published in the 2021 Annual Report. The document includes specific financial metrics such as revenue, net profit, and cash flow figures broken down quarterly, indicating substantive financial data. The document is about correcting the content of the annual report rather than announcing the publication or availability of the report. Therefore, it is not a mere announcement but a substantive correction to the Annual Report itself. Given the detailed financial data and the nature of the corrections, the document should be classified as an Annual Report (10-K). FY 2021
2022-05-27 Chinese
江苏四环生物股份有限公司关于对深圳证券交易所2021年年报问询函回复的公告
Annual Report Classification · 95% confidence The document is a detailed response to an inquiry letter from the Shenzhen Stock Exchange regarding the company's 2021 annual report. It contains extensive financial data, analysis of revenue, profit, cash flow, segment performance, and explanations of business operations and accounting treatments for the fiscal year 2021. The document includes auditor opinions and detailed financial tables, indicating it is part of the annual reporting process. The presence of the term '2021 年年报' (2021 annual report) and the detailed financial disclosures confirm this is related to the Annual Report. The document is lengthy (15,000 characters) and contains substantive financial data and analysis, not merely an announcement or certification. Therefore, it should be classified as an Annual Report (10-K). FY 2021
2022-05-27 Chinese
江苏世纪同仁律师事务所关于深圳证券交易所《关于对江苏四环生物股份有限公司2021年年报的问询函》所涉事项的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter from a law firm regarding an inquiry from the Shenzhen Stock Exchange about the 2021 annual report of Jiangsu Sihuan Bio. It references the 2021 annual report and discusses issues related to control and disclosure of shareholding and related legal compliance. The document is a legal opinion responding to a regulatory inquiry, not the annual report itself. It contains no financial statements or substantive financial data but rather legal analysis and confirmation of disclosures. The document length is 3398 characters, which is relatively short and consistent with a legal opinion letter. Therefore, it is best classified as a Regulatory Filing (RNS) because it is a regulatory compliance document and legal opinion related to the annual report inquiry, not the report itself or an audit report.
2022-05-27 Chinese

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.